TRAINING UPDATE

Lab Location: SGMC & WAH **Date Distributed:** 8/10/2018 **Department:** Core Lab **Due Date:** 8/31/2018

Implementation: 8/29/2018

DESCRIPTION OF PROCEDURE REVISION

Name of procedure:

Magnesium by Dimension Vista® System SGAH.C81 v3

Description of change(s):

Note change to Calibrator & QC stability, and freezer range Most other changes are format updates

Section	Reason
3.2	Remove specimen onboard stability
5.2, 6.2	Update storage
7.2	Add freezer requirements by product
10.6	Remove repeat value below AMR/CRR
14.2	Add interfering medications
15	Update CV% to match current PI
16	Update policy title
17	Update PI dates

This revised SOP will be implemented on August 29, 2018

Document your compliance with this training update by taking the quiz in the MTS system.

Technical SOP

Title	Magnesium by Dimension Vista® Sys	stem	
Prepared by	Ashkan Chini	Date:	6/22/2012
Owner	Robert SanLuis	Date:	6/12/2014

Laboratory Approval	Local Effective Dat	e:
Print Name and Title	Signature	Date
Refer to the electronic signature page for approval and approval dates.		

Review		
Print Name	Signature	Date

Form revised 2/02/2007

SOP ID: SGAH.C81 CONFIDENTIAL: Authorized for internal use only SOP Version # 3 Page 1 of 15

TABLE OF CONTENTS

Ι.	Test Information	2
2.	Analytical Principle	3
3.	Specimen Requirements	3
4.	Reagents	4
5.	Calibrators/Standards	4
6.	Quality Control	6
7.	Equipment And Supplies	8
8.	Procedure	9
9.	Calculations	10
10.	Reporting Results And Repeat Criteria	10
11.	Expected Values	11
12.	Clinical Significance	12
13.	Procedure Notes	12
14.	Limitations Of Method	12
15.	Safety	13
16.	Related Documents	13
17.	References	13
18.	Revision History	14
19.	Addenda	

1. TEST INFORMATION

Assay	Method/Instrument	Local Code
Magnesium	Dimension Vista® System	MG

Synonyms/Abbreviations	
MG	

Department	
Chemistry	

Form revised 2/02/2007

2. ANALYTICAL PRINCIPLE

The magnesium method is a modification of the methylthymol blue (MTB) complexometric procedure described by Connerty, Lau, and Briggs. The barium salt of ethylenebis (oxyethylenenitrilo) tetraacetic acid (Ba-EGTA) is used to reduce interference due to calcium which also reacts with MTB.

MTB forms a blue complex with magnesium. Calcium interference is minimized by forming a complex between calcium and Ba-EGTA (chelating agent). The amount of MG-MTB complex formed is proportional to the magnesium concentration and is measured using a bichromatic (600 and 510 nm) endpoint technique.

3. SPECIMEN REQUIREMENTS

3.1 Patient Preparation

Component	Special Notations
Fasting/Special Diets	N/A
Specimen Collection and/or Timing	Normal procedures for collecting and storing serum and plasma may be used for samples to be analyzed by this method.
Special Collection Procedures	N/A
Other	N/A

3.2 Specimen Type & Handling

Criteria	
Type -Preferred	Plasma (Lithium Heparin)
-Other Acceptable	Serum
Collection Container	Plasma: Mint green top tube (PST)
	Serum: Red top tube, Serum separator tube (SST)
Volume - Optimum	1.0 mL
- Minimum	0.5 mL
Transport Container and	Collection container or Plastic vial at room temperature
Temperature	
Stability & Storage	Room Temperature: 7 days
Requirements	Refrigerated: 7 days
	Frozen: 12 months
Timing Considerations	Serum or plasma should be physically separated from cells
	as soon as possible with a maximum limit of two hours
	from the time of collection.

n revised 2/02/2007

SOP ID: SGAH.C81

CONFIDENTIAL: Authorized for internal use only

Criteria	
Unacceptable Specimens	Specimens that are unlabeled, improperly labeled, or those
& Actions to Take	that do not meet the stated criteria are unacceptable.
	Request a recollection and credit the test with the
	appropriate LIS English text code for "test not performed"
	message. Examples: Quantity not sufficient-QNS; Wrong
	collection-UNAC. Document the request for recollection in
	the LIS.
Compromising Physical	Gross hemolysis. Reject sample and request a recollection.
Characteristics	Credit the test with the appropriate LIS English text code
	explanation of HMT (Specimen markedly hemolyzed)
Other Considerations	Allow Red Top or SST to clot completely prior to
	centrifugation.

NOTE: Labeling requirements for all reagents, calibrators and controls include: (1) Open date, (2) Substance name, (3) Lot number, (4) Date of preparation, (5) Expiration date, (6) Initials of tech, and (7) Any special storage instructions. Check all for visible signs of degradation. When placed onboard the analyzer, the instrument captures the date / time loaded and calculates and tracks the opened expiration.

4. **REAGENTS**

The package insert for a new lot of kits must be reviewed for any changes before the kit is used. A current Package Insert is included as a Related Document.

4.1 **Reagent Summary**

Reagents	Supplier & Catalog Number
Magnesium	Siemens, Flex® reagent cartridge, Cat. No. K3057

4.2 **Reagent Preparation and Storage**

Reagent	Magnesium	
Container	Reagent cartridge	
Storage	Store at 2-8°C	
Stability	 Stable until expiration date stamped on reagent cartridges. Sealed wells on the instrument are stable for 30 days. Open well stability: 7 days for wells 1 - 12 	
Preparation	All reagents are liquid and ready to use.	

5. CALIBRATORS/STANDARDS

CONFIDENTIAL: Authorized for internal use only Page 4 of 15

5.1 Calibrators/Standards Used

Calibrator	Supplier and Catalog Number
CHEM 1 CAL	Siemens Dimension Vista®, Cat. No. KC110B

5.2 Calibrator Preparation and Storage

Calibrator	CHEM 1 CAL	
Preparation	Allow to thaw and equilibrate to room temperature $(22-28^{\circ}\text{C})$ for 1 hour. Before use, gently invert the calibrator vials at least 10 times to ensure that the contents are thoroughly mixed. Do not vortex.	
Storage/Stability	• Store at -25 to -15°C	
	• Unopened Frozen: until expiration date on the box.	
	• Unopened Thawed: 30 days at 2-8°C	
	• Opened Calibrator: once the stopper is punctured, stable	
	for 7 days when stored on board the Dimension Vista	
	System.	

5.3 Calibration Parameter

Criteria	Special Notations	
Reference Material	CHEM 1 CAL	
Assay Range	0.3 - 10.0 mg/dL	
Suggested Calibration Level	See Reagent Package Insert for lot specific assigned values in mg/dL	
Frequency	 Every new reagent cartridge lot. Every 90 days for any one lot When major maintenance is performed on the analyzer. When control data indicates a significant shift in assay. 	
Calibration Scheme	2 levels, n = 5	

5.4 Calibration Procedure

Auto Calibration:

- 1. Place the required calibrator vials in a carrier. Make sure the barcode labels are entirely visible through the slots.
- 2. Place the carrier in the loading area.
- 3. Position the carrier with the labels facing away from the user.
- 4. Press the **Load** button.
- 5. Automatic calibration requires that calibrators be on the instrument. As the time for processing approaches, the instrument reviews onboard inventory for the appropriate calibrators.

rm revised 2/02/2007

SOP ID: SGAH.C81 CONFIDENTIAL: Authorized for internal use only SOP Version # 3 Page 5 of 15

Manual Calibration:

- 1. Verify that calibrators and reagents are in inventory on the instrument.
- 2. Press System > Method Summary > Calibration.
- 3. Select a method from the sidebar menu. Press the **Order Calibration** button on the screen.
- 4. Verify that the information on the screen is correct. Verify that the calibrator lot is correct using the drop-down menu.
 - a. When calibrating using Vials press **OK**.
 - b. When calibrating using Cups, check the Use Cups box. This displays the rack and cup position fields. For additional cups use the positions in ascending order. Be sure to use the number of calibration levels and cups as specified in the method IFU. Scan the rack barcode and place calibrator cups in an adapter in position 1 on a rack. Press **OK** and load the rack on the instrument.
- 5. The status field in the calibration screen changes sequentially to Awaiting Scheduling, Preparing Calibrators and Processing.

5.5 Tolerance Limits

IF	THEN
If result fall within assay-specific specification,	proceed with analysis
and QC values are within acceptable limits,	
If result falls outside assay-specific specification,	troubleshoot the assay and/or
or QC values are out of Acceptable limits,	instrument and repeat calibration

6. QUALITY CONTROL

6.1 Controls Used

Controls	Supplier and Catalog Number
Liquid Assayed Multiqual® Levels 1 and 3	Bio-Rad Laboratories Cat. No. 337 and 339

6.2 Control Preparation and Storage

Control	Liquid Assayed Multiqual, Levels 1 and 3	
Preparation	Allow the frozen control to stand at room temperature (18-25°C) for 30 minutes or until completely thawed. A precipitate may be present that dissolves upon mixing. Before loading vials, gently swirl the contents to ensure homogeneous with no visible sign of precipitate. (Do not use a mechanical mixer)	
Storage/Stability	Frozen : stable until the expiration date at -20 to -50°C.	
	Thawed and Unopened: When stored at 2-8°C and the stopper is not punctured, it will be stable for 30 days for MG This product can be used for 7 days when stored on-board the	

CONFIDENTIAL: Authorized for internal use only Page 6 of 15

Siemens Din	nension Vista at 2-8°C.
Thawed and Opened: Once the stopper is punctured, all	
analytes will	be stable for 5 days when stored at 2-8°C.
Store away f	rom light.

6.3 Frequency

Analyze all levels of QC material after every calibration and each day of testing (notated on the QC frequency sheets posted on the instruments).

Refer to the Dimension Vista® QC Schedule in the Laboratory policy Quality Control Program and in the Dimension Vista® Quick Reference Guide.

6.4 Tolerance Limits and Criteria for Acceptable QC

Step	Action	
1	Acceptable ranges for QC are programmed into the instrument's Quality Control software system and Unity Real Time, and may be posted near the instrument for use during computer downtime.	
2	 Run Rejection Criteria Anytime the established parameters are exceeded (if one QC result exceeds 2 SD), the run is considered out of control (failed) and patient results must not be reported. The technologist must follow the procedure in the Laboratory QC Program to resolve the problem. 	
3	 All rejected runs must be effectively addressed through corrective action. Steps taken in response to QC failures must be documented. Patient samples in failed analytical runs must be reanalyzed according to the Laboratory QC Program. Supervisors may override rejection of partial or complete runs only with detailed documentation and criteria for overrides that are approved by the Medical Director. Consult corrective action guidelines in Laboratory QC Program. Follow corrective action guidelines in the Laboratory QC Program. 	
	Corrective action documentation must follow the Laboratory Quality Control Program.	
4	Review of QC	
	QC must be reviewed weekly by the Group Lead or designee and monthly by the Supervisor/Manager or designee.	
	• If the SD and/or CV are greater than established ranges, investigate the cause for the imprecision and document implementation of corrective actions.	

vised 2/02/2007

SOP ID: SGAH.C81 CONFIDENTIAL: Authorized for internal use only SOP Version # 3 Page 7 of 15

6.5 Documentation

- QC tolerance limits are programmed into the instrument and Unity Real Time; it calculates cumulative mean, SD and CV and stores all information for easy retrieval.
- Quality control records are reviewed daily at the bench, weekly by the Group Lead or designee, and monthly by the Supervisor/Manager or designee.
- Refer to complete policies and procedures for QC documentation and for record retention requirements in the Laboratory QC Program.

6.6 Quality Assurance Program

- Each new lot number of reagent or new shipment of the same lot of reagent must be tested with external control materials and previously analyzed samples. Performance of the new lot must be equivalent to the previous lot; utilize published TEA for acceptability criteria.
- Training must be successfully completed and documented prior to performing this
 test. This procedure must be incorporated into the departmental competency
 assessment program.
- The laboratory participates in CAP proficiency testing. All proficiency testing materials must be treated in the same manner as patient samples.
- Monthly QC must be presented to the Medical Director or designee for review and signature.
- Monthly QC mean and SD are sent to Bio-Rad Laboratories for peer group comparison.
- Consult the Laboratory QC Program for complete details.

7. EQUIPMENT and SUPPLIES

7.1 Assay Platform

Dimension Vista® System

7.2 Equipment

- Refrigerator capable of sustaining 2–8°C.
- Freezer capable of sustaining range to not exceed -15 to -25°C for calibrator.
- Freezer capable of sustaining range not to exceed -20 to -50°C for QC product.
- Centrifuge

7.3 Supplies

- Aliquot Plates
- System Fluids
- Assorted calibrated pipettes (MLA or equivalent) and disposable tips

Form revised 2/02/2007

SOP ID: SGAH.C81 CONFIDENTIAL: Authorized for internal use only SOP Version # 3 Page 8 of 15

8. PROCEDURE

MG Flex® reagent cartridge Cat. No. K3057 is required to perform this test.

Magnesium is performed on the Dimension Vista® System after the method is calibrated (see Reference Material in Calibration section) and Quality Controls are acceptable.

NOTE: For all procedures involving specimens, buttoned lab coats, gloves, and face protection are required minimum personal protective equipment. Report all accidents to your supervisor.

8.1	Sample Processing	
1.	A sample rack holding tubes or cups is placed on the rack input lane.	
2.	The sample shuttle moves the rack to the barcode reader which identifies the rack and samples to the system.	
3.	The rack moves into the sample server and to the rack positioner.	
4.	At the same time, aliquot plates move from the aliquot loader into position.	
5.	The aliquot probe aspirates the sample from the tubes or cups and dispenses it into the wells of the aliquot plates.	
6.	After each aspirate-dispense action, the probe is thoroughly rinsed inside and out to prevent sample carryover.	
7.	When sample aspiration is completed, the sample server moves the rack back to the sample shuttle, where it is placed on the output lane and can be removed by the operator.	

8.2	Specimen Testing
1.	For QC placement and frequency, refer to the Dimension Vista® QC Schedule in the Laboratory QC Program.
2.	Follow the instructions, outlined in the Dimension Vista® Operator's Manual
3.	The instrument reporting system contains error messages to warn the user of specific malfunctions. Results followed by such error messages should be held for follow-up. Refer to the Dimension Vista® system manual "Error messages" section for troubleshooting.
4.	Follow protocol in Section 10.5 "Repeat criteria and resulting" for samples with results above or below the Analytical Measurement Range (AMR). Investigate any failed delta result and repeat, if necessary.
5.	Append the appropriate English text code qualifier messages to any samples requiring a comment regarding sample quality and/or any other pertinent factors.

Test Conditions		
Sample Volume:	1.5 μL	
Reagent 1 Volume:	60.0 μL	
Reagent 2 Volume:	60.0 μL	

CONFIDENTIAL: Authorized for internal use only

Page 9 of 15

SOP ID: SGAH.C81 SOP Version # 3 2/02/2007

Test Conditions		
Reaction Time: 1.9 minutes		
Test Temperature:	37°C	
Wavelength:	600 & 510 nm	
Type of measurement:	Bichromatic endpoint	

NOTE: In the event that the test system becomes inoperable, notify supervision or designee for further direction. Patient specimens must be stored in a manner that maintains the integrity of the specimen.

9. CALCULATIONS

The instrument automatically calculates the concentration of Magnesium in mg/dL.

10. REPORTING RESULTS AND REPEAT CRITERIA

10.1 Interpretation of Data

None required

10.2 Rounding

No rounding is necessary. Instrument reports results up to one decimal point.

10.3 Units of Measure

mg/dL

10.4 Clinically Reportable Range (CRR)

0.3 - 30.0 mg/dL

10.5 Review Patient Data

Each result is reviewed for error messages. Refer to the Dimension Vista system manual "Error messages" section for troubleshooting. Resolve any problems noted before issuing patient reports.

10.6 Repeat Criteria and Resulting

All repeats must replicate the original result within the total allowable error (TEa) of the assay. Refer to TEa listing for specific information.

Values that fall below or within the AMR or CRR may be reported without repeat. Values that exceed the upper ranges must be repeated.

Form revised 2/02/2007

SOP ID: SGAH.C81 CONFIDENTIAL: Authorized for internal use only SOP Version # 3

IF the result is	THEN	
< 0.3 mg/dL	Assure there is sufficient sample devoid of bubbles, cellular debris, and/or fibrin clots. Report as: < 0.3 mg/dL	
	On Board Automated Dilution:	
≥ 10.0 mg/dL	Results ≥ 10.0 mg/dL will automatically have repeat testing performed into the instrument using dilution factor of 2. No multiplication is necessary.	
	Manual Dilution:	
> 20.0 mg/dL	Using the primary tube, make the smallest dilution possible to bring the raw data within the AMR. Maximum allowable dilution: x 3	
	DILUENT: Reagent Grade Water	
	Enter dilution factor as a whole number. Re-assay. Readout is corrected for dilution.	
> 30.0 mg/dL	If the recommended dilution does not give results within the clinically reportable range, report as: "> 30.0 mg/dL-REP"	
	Bring to the attention of your supervisor prior to releasing result.	

Message	Code	
Verified by repeat analysis	Append –REP to the result.	

EXPECTED VALUES 11.

11.1 **Reference Ranges**

Age	Female	Male	
Adult (>18 years):	1.8 - 2.4 mg/dL	1.8 - 2.4 mg/dL	
Pediatric:			
18 years	1.5 - 1.9	1.6 - 2.1	
11 – 17 years	1.6 - 2.1	1.4 - 2.1	
4 – 10 years	1.6 - 2.5	1.5 - 2.2	
13 months – 3 years	1.5 - 2.2	1.6 - 2.2	
3-12 months	1.6 - 2.2	1.6 - 2.5	
0 – 90 days	1.5 - 2.1	1.5 - 2.2	

Critical Values 11.2

All ages, male and female:

 $\begin{array}{ll} Low: & \leq 1.0 \ mg/dL \\ High: & \geq 7.0 \ mg/dL \end{array}$

11.3 Standard Required Messages

None established

12. CLINICAL SIGNIFICANCE

Magnesium is involved in many enzymatic reactions of metabolism as an activating ion. Decreased levels of magnesium lead to muscle irritability, and possibly tetany, if not corrected. Elevated levels reduce muscle and nerve irritability, and at extremely high levels result in an anesthetic effect that could ultimately cause cardiac arrest. Magnesium may be increased in patients with kidney failure. Some conditions in which magnesium may be decreased include:

1) prolonged intravenous feeding, 2) chronic alcohol intoxication and alcoholic cirrhosis, 3) primary hyperaldosteronism 4) malabsorption syndromes 5) diabetic coma, and 6) hyperparathyroidism.

13. PROCEDURE NOTES

FDA Status: FDA Approved/clearedValidated Test Modifications: None

The instrument reporting system contains error messages to warn the operator of specific malfunctions. Any report slip containing such error messages should be held for follow-up. Refer to your Dimension Vista Operator's Guide.

The expected maximum observed standard deviations for repeatability using n = 5 replicates at the following MG concentrations are:

MG Concentration	Acceptable S.D. Maximum		
2.1 mg/dL	$0.2~{ m mg/dL}$		
10.5 mg/dL	1.3 mg/dL		

14. LIMITATIONS OF METHOD

14.1 Analytical Measurement Range (AMR)

0.3 - 10.0 mg/dL

14.2 Precision

	Mean	Standard Deviation (%CV)		
Material	mg/dL	Repeatability	Within-Lab	
Multiqual Control				
Level 1	1.1	0.05	0.06	
Level 2	2.5	0.07	0.07	
Level 3	4.1	0.08	0.10	

SOP ID: SGAH.C81 CONFIDENTIAL: Authorized for internal use only SOP Version # 3

Interfering Substances 14.3

Because magnesium is three times more concentrated in erythrocytes than in serum, hemolyzed samples will give spuriously elevated results.

HIL Interference:

The MG method was evaluated for interference according to CLSI/NCCLS EP7-A2. Bias, defined as the difference between the control sample (does not contain interferent) and the test sample (contains interferent), is shown in the table below. Bias exceeding 10% is considered "interference".

Substance tested	Substance Concentration	MG mg/dL	Bias %
Hemoglobin (hemolysate)	1000 mg/dL	1.9	<10
Bilirubin (unconjugated)	60 mg/dL	2.0	<10
Bilirubin (conjugated)	60 mg/dL	2.0	<10
Lipemia Intralipid®	3000 mg/dL	1.7	<10

Clinical Sensitivity/Specificity/Predictive Values 14.4

Not available

15. **SAFETY**

Refer to your local and corporate safety manuals and Safety Data Sheet (SDS) for detailed information on safety practices and procedures and a complete description of hazards.

16. RELATED DOCUMENTS

- Dimension Vista[®] Clinical Chemistry System Operator's Manual
 Dimension Vista[®] Calibration/Verification Procedure
- 3. Dimension Vista® Cal Accept Guidelines
- 4. Dimension Vista[®] Calibration summary
- 5. Dimension Vista® Sample Processing, Startup and Maintenance procedure
- 6. Laboratory Quality Control Program
- 7. QC Schedule for Siemens Dimension Vista®
- 8. Laboratory Safety Manual
- 9. Safety Data Sheets (SDS)
- 10. Dimension Vista® Limits Chart (AG.F200)
- 11. Quest Diagnostics Records Management Procedure
- 12. Dimension Vista® System Error Messages Chart
- 13. Centrifuge Use, Maintenance and Functions Checks (Lab policy)
- 14. Specimen Acceptability Requirements (Lab policy)
- 15. Repeat Testing Requirement (Lab policy)
- 16. Current Allowable Total Error Specifications at http://questnet1.qdx.com/Business Groups/Medical/qc/docs/qc bpt tea.xls
- 17. Current package insert MG Flex® Reagent Cartridge K3057

SOP ID: SGAH.C81 CONFIDENTIAL: Authorized for internal use only Page 13 of 15 SOP Version #

17. **REFERENCES**

- 1. Ghoshal, Amit K. and Soldin, Steven J., Evaluation of the Dade Behring Dimension® RxL: Integrated chemistry system-pediatric reference ranges. Clinica Chimica Acta 2003; 331:144.
- 2. Package Insert, MG Flex® Reagent Cartridge K3057, Siemens Healthcare Diagnostics Inc., 8/30/2017.
- 3. Package Insert, CHEM I CAL, Siemens Healthcare Diagnostics Inc., 07/2016.
- 4. Package Insert, Liquid Assayed Multiqual® Chemistry Controls, Bio-Rad Laboratories, 05/2017.

18. REVISION HISTORY

Version	Date	Section	Reason	Reviser	Approval
000	6/12/14		Update owner	L Barrett	R SanLuis
000	6/12/14	5.2	Update open calibrator stability	A Chini	R SanLuis
000	6/12/14	16	Update titles	L Barrett	R SanLuis
000	6/12/14	Footer	Version # leading zero's dropped due to new EDCS in use as of 10/7/13.	L Barrett	R SanLuis
1	8/2/16	Header	Add WAH	L Barrett	R SanLuis
1	8/2/16	3.2	Specify anticoagulant	L Barrett	R SanLuis
1	8/2/16	5.1	Update Catalog number	A Chini	R SanLuis
1	8/2/16	5.3, 14.1	Change assay range to match pkg insert	A Chini	R SanLuis
1	8/2/16	6.1, 6.2	Update QC product	A Chini	R SanLuis
1	8/2/16	6.4, 6.5	Replace LIS with Unity Real Time	A Chini	R SanLuis
1	8/2/16	7.2	Change freezer range to -50C	L Barrett	R SanLuis
1	8/2/16	10.4	Edit CRR	A Chini	R SanLuis
1	8/2/16	10.5	Move patient review from section 6	L Barrett	R SanLuis
1	8/2/16	10.6	Edit values of repeat criteria	A Chini	R SanLuis
1	8/2/16	14.2	Edit precision to match package insert	A Chini	R SanLuis
1	8/2/16	14.3	Delete EDTA interference	A Chini	R SanLuis
1	8/2/16	15	Update to new standard wording	L Barrett	R SanLuis
1	8/2/16	17	Update QC, PI revision dates	A Chini	R SanLuis
2	8/6/18	3.2	Remove specimen onboard stability	L Barrett	R SanLuis
2	8/6/18	5.2, 6.2	Update storage	L Barrett	R SanLuis
2	8/6/18	7.2	Add freezer requirements by product	L Barrett	R SanLuis
2	8/6/18	10.6	Remove repeat value below AMR/CRR	L Barrett	R SanLuis
2	8/6/18	14.2	Update CV% to match current PI	L Barrett	R SanLuis
2	8/6/18	16	Update policy title	L Barrett	R SanLuis
2	8/6/18	17	Update PI dates	L Barrett	R SanLuis

19. ADDENDA

None

rm revised 2/02/2007

SOP ID: SGAH.C81 CONFIDENTIAL: Authorized for internal use only SOP Version # 3 Page 15 of 15